Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793478312 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Overactive Bladder Symptoms ◽

Faculty of 1000 evaluation for A Randomized, Double-Blind, Placebo Controlled Trial of Adalimumab in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718022125.793480106 ◽

2013 ◽

Author(s):

Altaf Mangera

Keyword(s):

Interstitial Cystitis ◽

Controlled Trial ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Double Blind ◽

Bladder Pain ◽

PD01-01 RESULTS FROM A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE EFFICACY AND SAFETY OF INTRA-TRIGONAL INJECTION OF ONABOTULINUM TOXIN A IN PATIENTS WITH BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS.

The Journal of Urology ◽

10.1016/j.juro.2017.02.181 ◽

2017 ◽

Vol 197 (4S) ◽

Cited By ~ 1

Author(s):

Rui Pinto ◽

Daniel Costa ◽

Afonso Morgado ◽

Pedro Pereira ◽

João Silva ◽

...

Keyword(s):

Interstitial Cystitis ◽

Controlled Trial ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Efficacy And Safety ◽

Toxin A ◽

Double Blind ◽

Bladder Pain ◽

Double Blind Placebo ◽

Onabotulinum Toxin A

PD9-11 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF ADALIMUMAB IN THE TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME

The Journal of Urology ◽

10.1016/j.juro.2014.02.793 ◽

2014 ◽

Vol 191 (4S) ◽

Author(s):

Philip Bosch

Keyword(s):

Interstitial Cystitis ◽

Controlled Trial ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Double Blind ◽

Bladder Pain ◽

A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome

European Urology ◽

10.1016/j.eururo.2018.07.026 ◽

2018 ◽

Vol 74 (5) ◽

pp. 623-630 ◽

Cited By ~ 14

Author(s):

Philip C. Bosch

Keyword(s):

Interstitial Cystitis ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Double Blind ◽

Bladder Pain ◽

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793482693 ◽

2013 ◽

Author(s):

Hashim Hashim ◽

Riyad Almousa

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Overactive Bladder Symptoms ◽

Faculty Opinions recommendation of A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718022125.793482012 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Interstitial Cystitis ◽

Controlled Trial ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Double Blind ◽

Bladder Pain ◽

Re: A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome

European Urology ◽

10.1016/j.eururo.2018.10.050 ◽

2019 ◽

Vol 75 (3) ◽

pp. 534

Author(s):

Piotr Radziszewski ◽

Łukasz Zapała

Keyword(s):

Interstitial Cystitis ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Double Blind ◽

Bladder Pain ◽

Faculty of 1000 evaluation for A Randomized, Double-Blind, Placebo Controlled Trial of Adalimumab in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718022125.793480561 ◽

2013 ◽

Author(s):

Howard Goldman ◽

Kamran Sajadi

Keyword(s):

Interstitial Cystitis ◽

Controlled Trial ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Double Blind ◽

Bladder Pain ◽

OnabotulinumtoxinA 100U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

Yearbook of Urology ◽

10.1016/j.yuro.2014.03.010 ◽

2014 ◽

Vol 2014 ◽

pp. 65-67

Author(s):

E.S. Rovner

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Overactive Bladder Symptoms ◽